Press coverage about Karyopharm Therapeutics (NASDAQ:KPTI) has trended somewhat positive recently, according to Accern Sentiment. The research firm identifies positive and negative media coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Karyopharm Therapeutics earned a news sentiment score of 0.24 on Accern’s scale. Accern also gave headlines about the company an impact score of 45.4642718973457 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.

These are some of the news headlines that may have effected Accern Sentiment Analysis’s rankings:

Karyopharm Therapeutics (NASDAQ:KPTI) traded up 2.05% during midday trading on Wednesday, hitting $9.44. The stock had a trading volume of 102,630 shares. The stock has a 50 day moving average of $9.23 and a 200 day moving average of $10.21. Karyopharm Therapeutics has a 12 month low of $6.27 and a 12 month high of $14.63. The stock’s market cap is $444.79 million.

Karyopharm Therapeutics (NASDAQ:KPTI) last posted its quarterly earnings results on Thursday, May 4th. The company reported ($0.71) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.67) by $0.04. The firm had revenue of $0.07 million for the quarter, compared to analysts’ expectations of $0.02 million. Karyopharm Therapeutics had a negative return on equity of 72.41% and a negative net margin of 50,646.40%. During the same period in the prior year, the company earned ($0.75) earnings per share. Analysts expect that Karyopharm Therapeutics will post ($2.68) EPS for the current fiscal year.

KPTI has been the subject of a number of recent research reports. Zacks Investment Research upgraded Karyopharm Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, March 21st. Wedbush reiterated an “outperform” rating and set a $14.00 price objective on shares of Karyopharm Therapeutics in a research note on Wednesday, April 5th. Robert W. Baird reiterated an “outperform” rating and set a $15.00 price objective on shares of Karyopharm Therapeutics in a research note on Thursday, April 6th. Jefferies Group LLC reiterated a “buy” rating and set a $17.00 price objective on shares of Karyopharm Therapeutics in a research note on Friday, April 7th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $18.00 price objective on shares of Karyopharm Therapeutics in a research note on Monday, May 15th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, seven have issued a buy rating and one has given a strong buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average target price of $14.46.

ILLEGAL ACTIVITY NOTICE: “Karyopharm Therapeutics (NASDAQ:KPTI) Earns Daily News Sentiment Rating of 0.24” was first posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this report on another publication, it was stolen and reposted in violation of international trademark & copyright law. The correct version of this report can be read at https://www.thecerbatgem.com/2017/07/19/karyopharm-therapeutics-nasdaqkpti-earns-daily-news-sentiment-rating-of-0-24.html.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. It has discovered and is developing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein, XPO1.

Insider Buying and Selling by Quarter for Karyopharm Therapeutics (NASDAQ:KPTI)

Receive News & Stock Ratings for Karyopharm Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics Inc. and related stocks with our FREE daily email newsletter.